Close menu




BAYER AG NA O.N.

Photo credits: pixabay.com

Commented by Stefan Feulner on December 21st, 2021 | 13:03 CET

BioNTech, Memiontec, Bayer - Catastrophic conditions

  • Technology

There is no question that the Corona pandemic must be fought by all means. Nevertheless, apart from the virus and the question of vaccination, testing and boosters, there are far worse problems on our planet. For example, did you know that in the top daily news, it is reported that some 2.2 billion people have no sustainable, safe and readily available access to drinking water? Or that 361,000 children under the age of five die each year from diarrheal diseases caused by dirty water and contaminated food? The issue of water will be increasingly prominent in the headlines over the next few years. You can already invest in tomorrow's winners.

Read

Commented by Fabian Lorenz on December 14th, 2021 | 12:40 CET

BioNTech, Bayer, Ayurcann: From vaccination records to cannabis

  • Cannabis

The COVID-19 pandemic is dominating the headlines. There is no end in sight to the pandemic. The shares of BioNTech are benefiting from this. The Mainz-based Company has developed the most successful vaccine to date. The blockbuster is likely to remain in demand and generate billions in revenue for BioNTech. Thus, Berenberg sees a price target of USD 400. Health Minister Karl Lauterbach referred to a necessary vaccination rate of over 90% in the ARD program "Anne Will". BioNTech is currently expanding its production capacity. Just like Ayurcann. Because the legalization of cannabis opens the door to a billion-dollar market for the Canadian Company. Bayer also made headlines yesterday - the US Supreme Court is taking a closer look at the glyphosate dispute. That is new food for the gamblers. They have the Bayer share firmly in their grip.

Read

Commented by Stefan Feulner on December 10th, 2021 | 13:54 CET

Bayer, Almonty Industries, JinkoSolar - Still considerable room for improvement

  • Tungsten

Inflation is growing relentlessly. In November, Germany's barometer for price increases climbed to 5.2%; a level last reached 29 years ago. Rising energy prices and exploding commodity prices are found to be the culprits here. Given the energy turnaround, the materials required for this, such as lithium, copper and cobalt, are in fact close to their highs. However, tungsten, which will be essential for electromobility in the future, still has some catching-up potential.

Read

Commented by Stefan Feulner on December 2nd, 2021 | 11:02 CET

Bayer, Ayurcann, JinkoSolar - Excellent prospects

  • Cannabis

"Release the hemp!" cult presenter Stefan Raab called for the legalization of cannabis years ago in a song he produced himself. But not Jamaica, but the traffic light coalition with SPD, FDP and the Greens caused jubilation in the various communities. The release of the drug opens up great opportunities for young companies as well as investors. In contrast to Germany, other countries have already made more progress. Currently, the cannabis sector is in correction mode on the stock market, but the long-term prospects are excellent.

Read

Commented by Armin Schulz on November 29th, 2021 | 11:36 CET

MorphoSys, Osino Resources, Bayer - Profits through takeovers

  • Gold

The world's most expensive takeover occurred in Germany when the Vodafone Group acquired the Mannesmann Group for EUR 190 billion in 2000. Initially, Vodafone offered only EUR 100 billion. When a company wants to take over a listed company, it must make a public offer to shareholders. At this point, the buying party is usually already the major shareholder in the takeover target. As a rule, these offers are significantly higher than the current share price in order to make the deal palatable to the shareholders. Payment is made in cash, in shares of the acquiring Company or with a mix of both. Today, we look at three companies that are the subject of takeover rumors.

Read

Commented by Fabian Lorenz on November 11th, 2021 | 13:02 CET

Bayer, TUI, Sativa Wellness: Figures move share prices

  • Cannabis

The reporting season is drawing to a close. Overall, most companies have been convincing, and the stock markets have been very friendly in recent weeks. Bayer published positive quarterly figures, raised its forecast for the full year and thus convinced the analysts from DZ Bank. Sativa Wellness benefits from the boom around cannabis and CBD. The still-new boom is growing strongly and is already in the black. At TUI, the operating figures play less of a role. The development of the Corona figures and, thus, possible travel restrictions in the coming winter are more critical. Read more about all three shares here.

Read

Commented by Stefan Feulner on November 1st, 2021 | 13:20 CET

Bayer, MAS Gold, Salzgitter - Positive turnaround

  • Gold

At chemical and pharmaceutical giant Bayer, the mood continues to brighten following the important decision of the European Patent Office. Also, the number season, which has been running for weeks, gives the markets an additional boost with solid figures and forecast increases. New highs in the most critical global stock indices are the result. On the other hand, the high inflation rates are a cause for concern, although they continue to be underestimated by the monetary watchdogs. The still weak precious metals markets could therefore experience a boom in the coming months.

Read

Commented by Armin Schulz on October 20th, 2021 | 11:04 CEST

Bayer, Sativa Wellness Group, MorphoSys - Can the pharmaceutical industry benefit from the new German government?

  • Biotechnology

The federal election is over, and the pharmaceutical industry has to adjust to the new political constellation. The industry is facing change. Digitization is an important topic. To not lose even more researchers to foreign countries, approval processes must be accelerated and bureaucracy reduced. If we always acted as decisively as we did during the pandemic, much more could be achieved. The new federal government is flirting with the legalization of cannabis. If this were to happen, the market would probably be huge. The next four years promise to be exciting.

Read

Commented by Nico Popp on October 18th, 2021 | 10:44 CEST

BioNTech, Cardiol Therapeutics, Bayer: Where triple-digit returns beckon

  • Biotechnology

The pandemic is drawing to a close. Vaccination rates are high, and a new wave is - fortunately - not picking up speed. But in this environment, what is happening to many highly acclaimed pandemic stocks? Are vaccine manufacturers still interesting at the moment? We look at how the industry is faring and where opportunities can still be found.

Read

Commented by Armin Schulz on October 15th, 2021 | 12:19 CEST

Bayer, Water Ways Technologies, K+S - Will there be enough food for everyone in the future?

  • agritech

Humanity is growing and growing. In a few years, 10 billion people will populate the earth. The question then arises as to whether there will be enough food available in the future. One of the difficulties is climate change. If it gets hotter and hotter, less will grow, and if agricultural land becomes smaller, less food can be produced. To meet this challenge, yields on arable land must be increased. Fertilizers can help. Another critical factor will be water. Water is already scarce in some parts of the world, and drinking water is far from accessible to everyone everywhere. Today we analyze three companies that could play an important role in the future of food supply.

Read